TLDR:
> By day 300 of follow-up, 93 (8.3%) of 1,126 participants said they had received a diagnosis of long COVID by a provider. The cumulative incidence of long COVID by day 300 in those who took a 14-day course of metformin was 6.3% (95% confidence interval [CI], 4.2 to 8.2) compared to 10.4% (7.8 to 12.9) in the placebo group, or 39.4% lower.
Interestingly, half of the participants in the study (which took place starting in December of 2020) were unvaccinated. The researchers noted that metformin appears to have reduced the viral load greatly. I wonder if that is equally true for vaccinated and unvaccinated patients. It would seem plausible (not a doctor) that the reduction in viral load is related to the lower incidence of long COVID.
Now that we're in 2023, and pretty much everyone is either multiply-vaccinated or has had COVID, the study might turn out differently. If anyone has looked into the paper/data, I'd be interested to know whether the benefit is equal among vaccinated/non-vaccinated.